Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cayla Schnider

Physician Assistant Macon, GA Physician Assistant

NPI 1457800070 CMS profile 11062411

5430 Bowman Rd, Macon, GA 31210

Open in the dashboard

General payments

$6,474

305 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cayla Schnider of Macon, GA is reported in the CMS Open Payments database as having received $6,474 across 305 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,036 46
2024 General $1,764 77
2023 General $1,574 78
2022 General $1,368 68
2021 General $732 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cayla Schnider
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Cayla Schnider were reported at $1,036. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Cayla Schnider Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $732 $132 $37–$438 $132
2022 $1,368 $155 $48–$522 $149
2023 $1,574 $167 $52–$557 $160
2024 $1,764 $178 $55–$600 $164
2025 $1,036 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $700 29 payments
  2. Seattle Genetics, Inc. $387 14 payments
  3. Janssen Biotech, Inc. $356 21 payments
  4. Merck Sharp & Dohme Corporation $356 18 payments
  5. Pfizer Inc. $352 19 payments
  6. AbbVie, Inc. $299 14 payments
  7. Incyte Corporation $286 12 payments
  8. Daiichi Sankyo Inc. $252 12 payments
  9. Myriad Genetic Laboratories, Inc. $218 3 payments
  10. Regeneron Healthcare Solutions, Inc. $217 9 payments
  11. Other $3,050 154 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,986 298 payments
  2. Education $488 7 payments
Products named General payments · program years 2021–2025
  1. KISQALI $452 17 payments
  2. KEYTRUDA $341 17 payments
  3. LIBTAYO $217 9 payments
  4. TUKYSA $202 13 payments
  5. MyChoice CDx $184 1 payment
  6. JAKAFI $168 9 payments
  7. Lenvima $166 9 payments
  8. VENCLEXTA $165 7 payments
  9. XTANDI $161 9 payments
  10. BRUKINSA $157 8 payments
  11. Other $5,449 284 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

584

Median for Physician Assistant: 241

Drug cost

$1,734,733

Median for Physician Assistant: $4,110

Branded share of claims

24%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lenalidomide Generic 46 $660,727
Pomalyst Pomalidomide Brand 26 $595,746
Revlimid Lenalidomide Brand 28 $472,753
Ondansetron Hcl Generic 58 $1,450
Prochlorperazine Maleate Generic 66 $746
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 45 $568
Dexamethasone Generic 61 $460
Tramadol Hcl Generic 32 $328
Pregabalin Generic 15 $263
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 11 $245

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$5,176

Medicare's payments for the services billed

Medicare patients

56

Average age 74

Services billed

67

30 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 50%
Diabetes 43%
Cancer 43%
Arthritis 41%
Ischemic heart disease 36%
COPD 32%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 50 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $120
$120 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $115
$115 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $112
$112 — —
JAKAFI
  • Incyte Corporation $100
$100 — —
BRUKINSA
  • BeiGene USA, Inc. $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 50 with Patron

Records

305 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record